Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. GeNeuro SA
  6. News
  7. Summary
    GNRO   CH0308403085

GENEURO SA

(GNRO)
  Report
Real-time Euronext Paris  -  11:28 2022-12-09 am EST
1.550 EUR   +1.31%
11/17GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab
AQ
11/16GeNeuro Begins Recruitment for Trial to Assess Temelimab's Efficacy as Therapy for Long COVID-19
MT
11/16GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-Covid Assessing Temelimab
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

GeNeuro and Fondamental Foundation Announce the First Results of the Collaboration for the Development of Diagnostic and Therapeutic Options for Patients with Post-Covid Neuropsychiatric Syndromes

04/13/2022 | 01:30am EST

GeNeuro presented at the Schizophrenia International Research Society (SIRS) congress from April 6 to 10 in Florence, Italy, the first data resulting from their collaboration launched in 2021, in the context of COVID. The first results presented in Florence were based on the analysis of blood samples from 104 patients hospitalized between January and March 2021 for psychiatric disorders, either for the first time or because of relapses, in the psychiatry department of Prof. Leboyer in Créteil at Hôpital H. Mondor, and 63 controls. The objective of this analysis was to measure the coronavirus infection rate in a population with no reported COVID disease and to search for links between SARS-CoV-2 infection and the endogenous retroviral protein W-ENV.

The analyses were performed by the INSERM "We-Met" platform at the Paul Sabatier University in Toulouse. SARS-CoV-2 specific serological analyses showed that 82% of the patients admitted to the psychiatric ward had been exposed to the COVID-19 virus. The detection of W-ENV protein was positive in the serum of 40% of the patients studied, but almost exclusively and very significantly in patients seropositive for SARS-CoV-2 (p<0.01).

The presence of W-ENV protein in the blood was also strongly correlated with elevated levels of cytokines characteristic of innate inflammation such as TNF-a, IL-1ß or IL8 (p<0.0001 for all three). Studies published in 2021 had shown that W-ENV expression was triggered by SARS-CoV-2 in the white blood cells and tissues of about 20% of healthy donors, suggesting individual susceptibility. This protein was also detected in the blood of hospitalized COVID-19 patients where the amount of expression in lymphocytes was associated with disease progression severity.

The persistence of W-ENV expression long after the acute phase of the disease and its association with immunoinflammatory manifestations support the biological hypothesis of its importance in the long-term neuropsychiatric syndromes suffered by many post-COVID patients.


ę S&P Capital IQ 2022
All news about GENEURO SA
11/17GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First ..
AQ
11/16GeNeuro Begins Recruitment for Trial to Assess Temelimab's Efficacy as Therapy for Long..
MT
11/16GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the Fir..
CI
10/28Geneuro’S Protect-Ms Phase 2 Trial Data, Presented At the Ectrims 2022 Congress in..
CI
10/25The Karolinska Institutet's Academic Specialist Center to Present Results of GeNeuro's ..
AQ
10/25GeNeuro Will Present Phase IIb Safety and Efficacy Data on Temelimab from its ProTEct-M..
CI
10/24GeNeuro, financial information and business update for the third quarter 2022
AQ
10/18GeNeuro - Presentation at the International Society of NeuroVirology 2022 of top-line d..
AQ
10/17Geneuro : Inside Information / Other news releases
PU
09/30GeNeuro Reports 2022 Half-Year Results and Provides Corporate Update
AQ
More news
Financials
Sales 2022 - - -
Net income 2022 -23,8 M -25,1 M -25,1 M
Net cash 2022 1,99 M 2,10 M 2,10 M
P/E ratio 2022 -1,77x
Yield 2022 -
Capitalization 38,5 M 40,6 M 40,6 M
EV / Sales 2022 -
EV / Sales 2023 2,24x
Nbr of Employees 16
Free-Float 54,5%
Chart GENEURO SA
Duration : Period :
GeNeuro SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENEURO SA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,55 €
Average target price 5,55 €
Spread / Average Target 258%
EPS Revisions
Managers and Directors
Jes˙s Martin-Garcia Chairman & Co-Chief Executive Officer
Miguel Payro Chief Financial Officer
HervÚ Perron Chief Scientific Officer
David Leppert Chief Medical Officer
Michel Dubois Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GENEURO SA-56.34%40
MODERNA, INC.-27.28%70 958
IQVIA HOLDINGS INC.-25.42%39 082
LONZA GROUP AG-39.99%36 246
ALNYLAM PHARMACEUTICALS, INC.40.35%29 282
SEAGEN INC.-19.79%23 253